By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – As Illumina shareholders prepare for a vote that could determine the future of Roche's hostile bid for the San Diego company, an investment analyst today said that Roche is unlikely to make any headway in getting a deal done and only has a couple of other options.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.